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 Structured Abstract 
Background: Bariatric surgery has been shown to improve cardiovascular risk factors 
but long term benefit for survival and cardiovascular events are still uncertain. 
Methods: We searched MEDLINE and EMBASE for parallel group studies that 
evaluated the clinical outcomes associated with bariatric surgery as compared to non-
surgical treatment. Relevant studies were pooled using randomized effects meta-
analysis for risk of myocardial infarction, stroke, cardiovascular events and mortality. 
Results: 14 studies met the inclusion criteria, which included 29,208 patients who 
underwent bariatric surgery and 166,200 nonsurgical controls (mean age 48 years, 
30% male, follow up period ranged from 2 years to 14.7 years).  Four studies were 
considered at moderate-high risk of bias, while the ten studies were at moderate or 
lower risk of bias. Compared to nonsurgical controls there was more than 50% 
reduction in mortality among patients who had bariatric surgery (OR 0.48 95% CI 
0.35-0.64, I2=86%, 14 studies). In pooled analysis of four studies with adjusted data, 
bariatric surgery was associated with a significantly reduced risk of composite 
cardiovascular adverse events (OR 0.54 95% CI 0.41-0.70, I2=58%). Bariatric surgery 
was also associated with significant reduction in specific endpoints of myocardial 
infarction (OR 0.46 95% CI 0.30-0.69, I2=79%, 4 studies) and stroke (OR 0.49 95% 
CI 0.32-0.75, I2=59%, 4 studies).   
Conclusions: Data from observational studies indicates that patients undergoing 
bariatric surgery have a reduced risk of myocardial infarction, stroke, cardiovascular 
events and mortality compared to non-surgical controls. Future randomised studies 
should investigate whether these observations are reproduced in a clinical trials 
setting. 
 Introduction 
 
Obesity is a worldwide problem with significant consequences on individuals and 
society.  The global age-standardized prevalence of obesity has nearly doubled from 
6.4% in 1980 to 12% in 2008.[1] Obesity is associated with cardiovascular disease, 
type 2 diabetes, several cancers, diminished average life expectancy,[2] and 
significant impairments in quality of life.[3] In addition, overweight or obesity in 
young adulthood and middle age has long-term adverse consequences for health care 
costs in older age.[4] While people may reduce their weight by dieting, physical 
activity, behavioral modification or consumption of drugs such as orlistat, many 
people find it difficult to consistently maintain any reduction in weight.[5]  Bariatric 
surgery is an option that has been shown to be associated with significant weight 
reduction compared to non-surgical control groups, and potentially confers 
improvements in disease conditions associated with obesity.[6] 
 
The effect of bariatric surgery on a number of endpoints has been extensively studied 
in the literature.  Pontirroli et al conducted a systematic review and meta-analysis of 8 
studies with 44,022 participants and found that compared to controls, surgery was 
associated with a reduced mortality (OR 0.55 95% CI 0.49-0.63).[7] Another meta-
analysis has shown that bariatric surgery has significant benefits on cardiovascular 
risk factors including hypertension, diabetes and hyperlipidemia.[8] In addition, there 
is evidence to suggest that it results in resolution of major comorbidities including 
metabolic syndrome, non-alcoholic fatty liver disease, nephropathy, left ventricular 
hypertrophy and obstructive sleep apnea.[9] However, there has yet to be a systematic 
review which evaluates the impact of bariatric surgery on cardiovascular events. 
  
In this study, we performed a systematic review and meta-analysis to evaluate the 
impact of bariatric surgery on long-term incident cardiovascular disease and mortality. 
 Methods 
 
Eligibility criteria 
We selected randomized trials and controlled observational studies (case-control or 
cohort design) that evaluated the association of bariatric surgery and clinical 
outcomes.  The following criteria were used for inclusion: 
1. sample size of >100 participants undergoing bariatric surgery. 
2. control group consisting of participants with non-surgical management, either 
in the same healthcare setting or as community-based controls. 
3. aimed to evaluate one of the following outcomes: myocardial 
infarction/ischemic heart disease/coronary heart disease, stroke or mortality. 
 
There was no restriction on whether the study has to be prospective or retrospective 
nor were there any restriction on the type of bariatric surgery. 
 
Search strategy 
We searched MEDLINE and EMBASE from inception up to August 2013 (NHS 
Evidence) with no language limitations using the broad free-text and indexing search 
terms [(bariatric surgery) AND ((acute coronary syndrome) OR (ischemic heart 
disease) OR (ischaemic heart disease) OR (coronary heart disease) OR (stroke) OR 
(cerebrovascular accident) OR (mortality) OR (cardiovascular disease))] 
(Supplementary Data 1).  In addition, we signed up with PubMed to receive 
automated electronic notifications for any new articles containing the ‘bariatric 
surgery’.  Bibliographies of included studies and recent review articles were checked 
for additional relevant studies. 
  
Study selection and data extraction 
Two reviewers (CSK and AP) evaluated all titles and abstracts for studies that met the 
inclusion criteria, and excluded any articles that clearly did not meet the selection 
criteria. The potential inclusions were checked by one author (YKL).  Full reports 
(where available) of potentially relevant studies were retrieved and independently 
checked for eligibility. Data from the included studies were then extracted by one of 
three reviewers (CSK or AP or MAK) who collected information on study design, 
drug exposure, study location, characteristics of participants onto a pre-formatted 
spreadsheet. The data table was then checked (in an unblinded manner) by at least one 
other reviewer (MAM or YKL). For the outcomes data, CSK and YKL independently 
extracted odds ratios (unadjusted or adjusted) where available; otherwise raw numbers 
were recorded to enable calculation of unadjusted odds ratios.  If a study had two or 
more groups of control participants, we pooled the data together to create a single 
comparator arm. 
 
Any uncertainties or discrepancies were resolved through re-checking against the 
source papers, and through discussion with another reviewer. Also, we contacted 
authors if there were any areas that required clarification. 
 
Assessment of risk of bias 
We developed our risk of bias assessment considering the recommendations of the 
Cochrane Adverse Effects Methods Group. Here, our risk of bias assessment included 
the selection of treatment group (bariatric surgery) and control group (no bariatric 
surgery), the ascertainment of clinical outcome, the extent of loss to follow up, the use 
 of propensity matching or adjustment for confounders and the generalizability of the 
study.[10] Generalizability was assessed by considering whether the treatment group 
and control group were representative of the obese patients treated with surgery and 
obese patients living in the community, respectively.  We aimed to generate funnel 
plots to assess the possibility of publication bias, provided that there were >10 studies 
available in the meta-analysis, with no evidence of substantial statistical 
heterogeneity.[11] 
 
Data analysis 
We used RevMan 5.2. (Nordic Cochrane Centre) to conduct random effects meta-
analysis using inverse variance method for pooled odds ratios (OR). We assumed 
similarity between the risk ratio and odds ratio because the incidence of adverse 
outcomes was low.[12] We evaluated both adjusted and unadjusted data from primary 
studies, although we preferentially used adjusted data where available. 
 
Statistical heterogeneity was assessed using I2 statistic,[13] with I2 values of 30-60% 
representing a moderate level of heterogeneity. Pre-specified sensitivity analysis was 
performed by evaluating the effect of using adjusted as opposed to crude estimates, 
and with exclusion of studies at moderate-high risk of bias. We also aimed to consider 
non-diabetic and diabetic cohorts separately. 
 Results 
 
Our search yielded 2764 potentially relevant articles and after removal of duplicates 
there were 2295 titles and abstracts, which were screened.  There were 30 potentially 
relevant articles and the full text of these articles was retrieved and 14 studies met the 
inclusion criteria after full text review.[14-28]  The process of study selection is 
shown in Figure 1.  
 
The available study designs consisted of three prospective cohorts [15, 20,26,27] and 
6 retrospective cohort [16,19,22,23,25], plus 5 cohort studies [17,18,21,24,26] where 
it was unclear if they were prospective or retrospective.  These studies took place 
between 1984 and 2011 in USA, Canada, Italy, Australia and Sweden.  There were a 
total of 195,408 participants (range 289 to 66,109 participants) with 29,208 patients 
undergoing bariatric surgery and 166,200 nonsurgical controls.  The mean age of 
participants in these studies was 48 years and 30% of participants were male. Study 
characteristic are summarized in Table 1. 
 
The quality assessment of the included studies is shown in Table 2.  Some extent of 
lost to follow up was present in four studies [15,17,25,28], with the greatest loss seen 
in Sowemimo 2007 (>10% of cohort with missing data) [28]. Four studies presented 
unadjusted results for some of the outcomes.[15,18,20,21]  Overall, four studies were 
considered to be of moderate-high risk of bias due to lack of adjustment for 
confounders or substantial loss to follow-up ,[15,18,20,28] while the others were at 
moderate or lower risk of bias. 
 
 The types of bariatric surgery and control groups, their follow up and outcome events 
or risk estimates are shown in Table 3.  Three studies did not specifically specify the 
type of bariatric surgery performed.[16,21,22]  Two studies only included obese 
participants with type 2 diabetes[16,21] and one study used orthopedic and 
gastrointestinal surgical patients as control groups.[25] The follow up of the included 
studies ranged from up to 2 years to over 14.7 years.  All include studies reported 
mortality outcome, and four studies evaluated myocardial infarction and stroke 
events, as well as a cardiovascular composite which typically consisted of mortality, 
myocardial infarction and stroke.[14,21,25-27] 
 
Mortality outcomes 
The analysis of risk of mortality with and without bariatric surgery is shown in Figure 
2.  The absolute event rates for each study for relevant outcomes are reported in 
Supplementary Table 1. Compared to nonsurgical controls, there was more than 50% 
reduction in mortality amongst patients who underwent bariatric surgery (OR 0.48 
95% CI 0.35-0.64, I2=86%, crude rate 1,059/29,208 (3.6%) vs. 18,962/166,200 
(11.4%), 14 studies). The pooled estimate from adjusted data yielded a more 
conservative and less heterogeneous association, OR 0.60 (95% CI 0.49 -0.74, 
I2=64%, crude rate 998/24,967 (4.0%) vs. 12,210/146,264 (8.3%), 10 studies) than the 
unadjusted estimates. (Figure 2) 
 
We also looked at subgroup of studies based on risk of bias, presence of diabetes 
mellitus, or on selection of controls. Exclusion of four studies with moderate-high risk 
of bias showed that the there was a significant reduction in mortality (adjusted OR 
0.67 95% CI 0.59 – 0.77, I2=25%, crude rate 1,013/26,639 (3.8%) vs. 13,179/159,523 
 (8.3%)). There were insufficient studies (two studies) to statistically pool to evaluate 
the risk of mortality and only included patients with diabetes. The study that had 
adjusted for confounders showed a non-significant trend towards reduction of 
mortality with bariatric surgery (OR 0.54 95% CI 0.23-1.28, crude rate 5/1,395 
(0.4%) vs. 484/62,322 (0.8%)) [16] while the other study showed a significant 
reduction in mortality with surgery (OR 0.20 95% CI 0.15-0.27, crude rate 41/2,580 
(1.6%) vs. 985/13,371 (7.4%)).[21] One other study used non-bariatric surgical 
controls which showed a non-significant trend towards reduction of mortality with 
bariatric surgery (OR 0.60 95% CI 0.0.34-1.06, crude rate 82/4,747 (1.7%) vs. 
358/4,393 (8.1%)).[25]   
 
Cardiovascular endpoints 
Four studies were included in the evaluation of the risk of the composite 
cardiovascular adverse event endpoint. All four studies presented adjusted risk 
estimates for the composite endpoint, and we found a significant reduction in risk 
associated with bariatric surgery (OR 0.54 95% CI 0.41-0.70, I2=58%, crude rate 
407/17,262 (2.4%) vs. 1,108/27,726 (4.0%)) (Figure 3).   
 
Bariatric surgery was associated with significant reduction in myocardial infarction 
and stroke (Figures 4 and 5).  Four studies with similar nonsurgical obese controls 
were pooled and there was a significant associated reduction in myocardial infarction 
(OR 0.46 95% CI 0.30-0.69, I2=79%, crude rate 226/17,262 (1.3%) vs. 691/27,726 
(2.5%), 4 studies).  The pooled estimate from studies with adjusted data yielded more 
conservative association of bariatric surgery with myocardial infarction (OR 0.58 95% 
CI 0.45-0.74, I2=44%, crude rate 218/14,682 (1.5%) vs. 450/14,355 (3.1%), 3 studies) 
 as compared to unadjusted estimates (OR 0.17 95% CI 0.08-0.35, crude rate 8/2,580 
(0.3%) vs. 241/13,371 (1.8%), 1 study).  For the stroke endpoint, pooled results of the 
same four studies yielded a significant associated reduction in stroke (OR 0.49 95% 
CI 0.32-0.75, I2=59%, crude rate 129/17,262 (0.7%) vs. 405/27,726 (1.5%), 4 
studies).  Again, pooled estimates using adjusted data yielded more conservative 
estimates of benefit associated with bariatric surgery (OR 0.63 95% CI 0.49-0.80, 
I2=0%, crude rate 118/14,682 (0.8%) vs. 191/14,355 (1.3%), 3 studies) as compared 
to unadjusted estimates (OR 0.26 95% CI 0.14-0.48, crude rate 11/2,580 (0.4%) vs. 
214/13,371 (1.6%)).
 Discussion 
 
This is the first meta-analysis demonstrating that bariatric surgery is associated with a 
reduced risk of myocardial infarction, stroke and composite adverse cardiovascular 
events. The reduction in risk of these events was approximately 50% after bariatric 
surgery compared to non-operated cohorts.  In terms of absolute event rates, we found 
that there were lower fraction of events in the bariatric surgery group compared to 
non-operated overweight control groups for all outcomes (mortality 3.6% vs. 11.4%, 
cardiovascular events 2.4% vs. 4.0%, myocardial infarction 1.3% vs. 2.5% and stroke 
0.8% vs. 1.5%).  We found similar reductions for risk of mortality. The magnitude of 
the effect estimates was greatest in studies with unadjusted estimates but the 
consideration of only adjusted estimates yielded significant reductions in all adverse 
events.  These finding suggest that patients who are both candidates for bariatric 
surgery and are at high risk of cardiovascular events should have bariatric surgery. 
 
Our study finding of reduction in CV events with bariatric surgery is supported by the 
findings of several existing studies which examined the effect of surgery on 
intermediate risk factors for CVD.  A recent meta-analysis by Gloy et al included 11 
randomized trials with 796 participants, and found that bariatric surgery was 
associated with significant reductions in weight, plasma triglyceride levels, plasma 
LDL cholesterol levels, HbA1c levels and increases in plasma HDL levels and rates 
of remission of diabetes but no significant difference in plasma cholesterol.[29]  
Another systematic review evaluated the effect of bariatric surgery on 73 different 
cardiovascular risk factors in 18 studies with 19543 participants.[8]  The key findings 
of this meta-analysis was that bariatric surgery was associated with reduction of  
 weight, hypertension, diabetes, hyperlipidaemia and significant improvements in 
echocardiographic parameters.  Similar findings were found in a recent meta-analysis 
and meta-regression which found that bariatric surgery has early beneficial impacts on 
type 2 diabetes, hypertension and hyperlipidaemia.[30]  While these systematic 
reviews consistently show that bariatric surgery is associated with significant 
improvements in cardioprotective risk factors none of them reported the effect on 
future cardiovascular event. 
 
The effects of bariatric surgery at physiological and cellular levels has been 
previously reviewed.[31]  It directly reduces the number of adipocytes which leads to 
decreased levels of leptin and resistin [32,33] and studies suggest that these hormones 
may have a role in atherogenesis [34, 35]. In addition, surgery impacts the 
endothelium directly causing decreases in E-selectin, P-selectin and ICAM-1 [36-38] 
which  are believed to be the markers that reflect the level of established 
cardiovascular risk [39].  The intervention also appears to reduce systemic 
inflammation and oxidative stress which are important processes in atherosclerosis;  
reduction in the levels of C-reactive protein, siallic acid, PAI-1, malondialdehyde and 
von Willebrand factor levels have been previously reported.[36,40]  In addition, 
bariatric surgery also has positive effects on other factors which increase 
cardiovascular risk such as athersclerotic load, insulin sensitivity and left ventricular 
function.[31]  Furthermore, post surgery weight reduction may improve physical 
activity, image and motivation to maintain healthier lifestyles. 
 
In terms of absolute event rates, we found that there were lower fraction of events in 
the bariatric surgery group compared to non-operated overweight control groups for 
 all outcomes.  However, the mortality rate is still much higher than that of the general 
population aged 15 to 60 in America (0.5%) and England (0.4%) (WHO).  We are 
also able to estimate, based on the mortality rate in a community cohort of severely 
obese patients,[14] a number needed to treat (NNT) of 59 (95% CI 46-91) with 
bariatric surgery to prevent one death over a seven year follow-up period.  This should 
be set in the context of statin therapy in patients with cardiovascular risk factors, 
where we have estimated (based on the pooled mortality rates in the meta-analysis by 
Brugts et al.)  an NNT of 174 (95% CI 110 – 428) to prevent one death with 4.1 years 
of continued statin intake.[41] 
 
Our study has several strengths.  We were able to include a total sample size of nearly 
200,000 (29,208 cases of bariatric surgery and 166,200 nonsurgical controls) with a 
follow up period that ranged from 2 years to 14.7 years which allowed capture of a 
enough cardiovascular events.  In addition, our analysis allowed for evaluation of the 
risk of myocardial infarction, stroke, cardiovascular events and mortality.  We were 
also able to consider the effects of adjustment and study quality in our analyses.  
 
Study limitations  
Our study has several limitations.  All the included studies were observational in 
nature as the randomized controlled trial of bariatric surgery did not capture sufficient 
cardiovascular events.  Furthermore, there is high level of heterogeneity as there were 
different methods that were used to identify non-surgical controls.  It is possible that 
in the absence of randomization patients may be selectively chosen for bariatric 
surgery because they are more likely to have positive outcomes after surgery.  While 
some of the included studies did adjust for potential confounders it is possible that 
 there are some unmeasured confounders which could not be fully accounted for.  
Moreover, the quality of the studies varied, and only three studies were considered to 
be of low to moderate risk of bias. Nevertheless, the mortality and cardiovascular 
benefits associated with bariatric surgery remained significant even after we excluded 
moderate-high risk studies from all the meta-analyses.  
 
Future studies 
Future research should be conducted to evaluate the long-term effects of bariatric 
surgery particularly through high-quality clinical trials such as the ongoing open 
randomized controlled trial, DiaSurg 2, which evaluates surgical vs. medical treatment 
of insulin dependent type 2 diabetes mellitus patients and follows participants for up 
for 8 years and measures outcomes such as cardiovascular death, myocardial 
infarction, non-fatal stroke.[42] 
 
Conclusions 
In conclusion, current observational studies provide consistent evidence that morbidly 
obese patients undergoing bariatric surgery have lower rates of myocardial infarction, 
stroke, cardiovascular events and mortality compared to matched non surgical 
controls (mortality 3.6% vs. 11.4%, cardiovascular events 2.4% vs. 4.0%, myocardial 
infarction 1.3% vs. 2.5% and stroke 0.8% vs. 1.5%).  Whilst, our data does not infer a 
causal relationship, our analysis suggests that bariatric surgery may be beneficial 
particularly in morbidly obese patients at risk of future cardiovascular events. 
Whether or not these reductions in clinical events are also observed in prospective 
randomized studies should be evaluated.  
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Supplement Data 1: Search Strategy
 Table 1: Study design, sample size and participants 
Study Design Dates Country Sample size Age % Male Participants 
Adams 2007 Matched 
retrospective 
cohort study. 
1984 to 
2002. 
Utah, USA. 7925 surgery, 
7925 control. 
39 16 Bariatric surgical patients matched to 
severely obese controls (BMI≥35) based 
on age, gender, BMI and year of 
surgery/application. 
Adams 2012 Prospective 
cohort study. 
July 2000 
to June 
2011. 
Utah, USA. 418 surgery, 
417 (control 
1)and 321 
(control 2). 
45 18 Bariatric surgery and nonsurgical control 
seeking bariatric surgery and those 
recruited from Utah Health Family Tree 
Program with BMI≥35. 
Arterburn 
2013 
Retrospective 
cohort study. 
2005 to 
2008. 
Minnesota, Seattle, 
California, USA. 
1395 surgery, 
62,322 control. 
49 27 Bariatric surgery and nonsurgical 
treatment control both groups were 
severely obese adults (BMI>35) with 
type 2 diabetes. 
Busetto 
2007 
Matched 
cohort study. 
Jan 1994 
to Dec 
2001. 
Padova, Italy. 821 surgery, 
821 control. 
41 25 Surgical patients compared to gender, 
age and BMI matched patients. 
Christou 
2004 
Matched 
cohort study. 
Jan 1986 
to June 
2002. 
Montreal, Canada 1,035 surgery, 
5,746 control. 
46 36 Bariatric surgery compared to 
nonsurgical treatment matched based on 
age, gender and date of diagnosis of 
morbid obesity. 
Flum 2004 Retrospective 
cohort study. 
1987 to 
2001 
Washington, USA. 3,328 surgery, 
62,781 control. 
47 35 Surgical patients and patients of similar 
age with diagnosis of obesity or morbid 
obesity without surgery. 
Gentileschi 
2012 
Prospective 
cohort study. 
Jan 2003 
to Nov 
2011. 
Italy. 208 surgery, 81 
not operated. 
NA 28 Bariatric surgery compared to 
nonsurgical treatment. 
Johnson 
2013 
Retrospective 
matched 
cohort. 
1996 to 
2009. 
South Carolina, USA. 2,580 surgery, 
13,371 control. 
51 31 Bariatric surgery compared to 
nonsurgical treatment and all patients 
had type 2 diabetes and moderate to 
severe obese adults. 
 Maciejewski 
2011 
Retrospective 
cohort study. 
Jan 2000 
to Dec 
2006. 
USA (Veterans Affairs 
medical centers). 
847 surgery, 
847 control. 
49  74  Bariatric surgery compared to 
nonsurgical treatment with BMI >35. 
Miranda 
2012 
Retrospective 
cohort study. 
1990 to 
2009. 
Rochester, Minnesota, 
USA. 
2,020 surgery, 
2,907 control. 
56 30 Bariatric surgery compared to 
nonsurgical treatment.  Patients were >18 
years of age and had BMI>35. 
Peeters 
2007 
Two cohort 
observational 
study. 
Jan 1993 
to Apr 
2005. 
Melbourne, Australia. 966 surgery, 
2,119 control. 
53 23 Gastric banding patients compared to age 
and BMI matched population cohort 
(BMI>35).   
Scott 2013 Retrospective 
cohort study. 
Jan 1996 
to Dec 
2008. 
Greenville, South Carolina, 
USA. 
4,747 surgery, 
4,393 control. 
54  20 Bariatric surgery compared to 
orthopaedic and gastrointestinal surgery 
control.  Age 40-79 years with morbid 
obesity. 
Sjostrom 
2007 and 
2012 
Prospective 
matched 
cohort. 
Sept 1987 
to 2005-
2009. 
Sweden (25 public surgical 
departments and 480 
primary health care 
centres). 
2,010 surgery, 
2,037 control. 
48 29 Bariatric surgery compared to 
nonsurgical treatment.  Age 37-60 years 
and BMI >34 for men and >38 for 
women. 
Sowemimo 
2007 
Retrospective 
cohort study. 
1997 to 
2006. 
Connecticut, USA. 908 surgery, 
112 control. 
44 27 Bariatric surgery compared to 
nonsurgical treatment. 
 
 
 Table 2: Quality assessment of included studies 
Study Ascertainment of controls. Ascertainment of 
surgery. 
Ascertainment of outcomes. Lost to follow 
up. 
Use of propensity matching or 
adjustment for confounding. 
Generalizability of 
findings  
Risk of bias. 
Adams 2007 Yes. Self-reported BMI 
≥35 randomly selected 
from among applicants for 
driver's license or 
identification card. 
No. Unclear 
description of how 
ascertained. 
Yes. Death is obtained from the 
National Death Index. 
Unclear. No 
loss to follow 
up reported. 
Yes. Matching for sex, BMI, self-
reported BMI, age and year. 
Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate 
Adams 2012 Yes. All participants 
underwent a baseline 
examination at the 
University of Utah Center. 
Yes. All participants 
underwent a baseline 
examination at the 
University of Utah 
Center. 
Yes. Death is obtained from the 
National Death Index. 
No. 130 did 
not complete 
examination at 
6 years. 
No. Crude, unadjusted results. Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate-
high. 
Arterburn 
2013 
Yes. Identification from 
electronic medical records. 
Yes. Identification 
from ICD-9 codes 
and CPT-4 
procedure codes. 
Yes. Death ascertained from medical 
databases and linking to stat death 
indices in California and Minnesota. 
Unclear, not 
reported. 
Yes. Unclear which adjusted 
model used but would have at least 
had site, gender, age, year, years 
since diabetes diagnosed, HbA1c, 
use of diabetic medications. 
No. Only 
generalizable to 
diabetes patients. 
Moderate. 
Busetto 
2007 
Yes. morbidly obese 
patients enrolled at 6 
tertiary obesity care centers 
not using bariatric surgery. 
Yes. Obese patients 
undergoing surgery 
at a single centre. 
Yes. Patients were seen regularly in 
outpatient basis. 
No. 41 
unknown vital 
status. 
Yes. Adjusted for gender, age 
class, and BMI class. 
Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate. 
Christou 
2004 
Yes. Use of provincial 
health insurance database. 
Yes. Use of 
provincial health 
insurance database. 
Yes. In surgical cohort, vital status 
was mainly determined as part of the 
routine clinical follow up by direct 
visual or telephone interview.  
Interviews with the Town Office of 
the municipality of the most recent 
residence.  Death certificates were 
obtained form the Local Health 
Authorities of the municipalities. 
Unclear. Not 
reported. 
No. Matched for age, gender and 
duration of follow up but not 
adjusted. 
Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate-
high. 
Flum 2004 Yes. Identification from 
ICD-9 codes and 
Washington State 
Comprehensive Hospital 
Abstract Reporting System 
reports. 
Yes. Identification 
from ICD-9 codes. 
Yes. Mortality derived from 
Washington State vital records 
database. 
Survival 
analysis was 
based on 
patients who 
were alive 
from >12 
months after 
the procedure. 
Yes. Adjusted for age, gender and 
comorbidity index. 
Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate. 
 Unclear loss to 
follow-up. 
Gentileschi 
2012 
Unclear. Likely reliable 
because prospective study. 
Unclear. Unclear. Unclear. Not 
reported. 
No. Crude, unadjusted results. Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate-
high 
Johnson 
2013 
Yes. Selected from uniform 
billing database. 
Yes. Identification 
from ICD-9 codes. 
Yes. Death obtained from South 
Carolina Department of Health and 
Environmental Control. 
Yes. 64 lost to 
follow up. 
Propensity score adjusted data 
available for composite 
macrovascular events but not for 
specific outcomes. 
No. Only 
generalizable to 
diabetes patients. 
Moderate. 
(low-
moderate 
for 
composite 
outcomes) 
Maciejewski 
2011 
Yes. Identified from 
Veterans Affairs registry. 
Yes. Identified from 
a database using 
ICD-9 and Current 
Procedural 
Terminology-4 
codes. 
Yes. Nurse contacted the patient or 
family 30 days after the operation 
and updated mortality was checked 
against the Veteran's Affairs vital 
status database. 
Not applicable 
as 
retrospective 
matched 
analysis. 
Yes. Adjusted for age, sex, self-
reported race, marital status, BMI, 
comorbidity burden and Veterans 
Integrated Service Network of 
residence. 
Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Low-
moderate 
Miranda 
2012 
Yes. Patients in nutrition 
clinic at Mayo clinic. 
Yes. Patients in 
nutrition clinic at 
Mayo clinic. 
Yes. Data from Mayo Clinic registry 
database and Accurint (web-based 
resource). 
Unclear. Not 
reported. 
Yes. Adjusted for propensity score. Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate 
Peeters 
2007 
Yes. Data recorded in face 
to face interview and 
information collected 
through questionnaire. 
Yes. Data recorded 
in interview and 
information 
collected through 
questionnaire. 
Yes. Annual follow-up visits to 
clinic or telephone call to confirm 
vital status.  These were matched to 
Victoria Registry of Births, Deaths 
and Marriages for matching. 
Yes. 26 lost to 
follow up. 
Yes. Adjusted for age, sex and 
initial BMI. 
Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate 
Scott 2013 Yes. Ascertained by ICD-9 
codes for orthopaedic and 
gastrointestinal procedure 
from the South Carolina 
Office of Research and 
Statistics. 
Yes. Ascertained by 
ICD-9 codes for 
primary bariatric 
procedure from the 
South Carolina 
Office of Research 
and Statistics. 
Yes. Death obtained from South 
Carolina Department of Health and 
Environmental Control's Office of 
Vital Statistics. 
No. 1424 
excluded (9%). 
Adjusted for age, gender and 
history of cardiovascular disease, 
hyperlipidaemia, and diabetes 
mellitus. 
No. Surgical 
controls used. 
Low-
Moderate. 
Sjostrom 
2007 and 
2012 
Yes. Ascertainment at 
baseline examination. 
Yes. Ascertainment 
at baseline 
examination. 
Yes. Physical examination and 
questionnaires used to follow up 
patients. 
Yes. 99% 
follow up rate. 
Yes. Adjusted for sex, age, MI, 
stroke, diabetes, smoking, lipid 
lowering medication, 
antihypertensives, insulin, BMI, 
waist, hip, systolic blood pressure, 
Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Low-
moderate 
 total cholesterol, HDL cholesterol 
and triglycerides. 
Sowemimo 
2007 
Yes. Telephone interviews 
were conducted. 
Yes. Bariatric 
database review. 
Yes. Using Social Security Death 
Index. 
Missing data 
on 165 patients 
(>10% of 
cohort). 
Yes. Adjusted for age, gender and 
body mass index. 
Yes. Likely that 
controls are 
potential candidates 
for surgery. 
Moderate-
high.. 
ICD=International Classification of Disease, MI=myocardial infarction, BMI=body mass index, HDL=high density lipoproteins 
 
 Table 3: Treatment groups, follow up and results 
Study Type of surgery Type of control Follow up Outcomes 
Adams 2007 Roux-en-Y gastric bypass 
surgery performed by a single 
Utah surgical practice of six 
experienced surgeons. 
Randomly selected driving 
license applicants with self-
reported BMI of ≥35. 
Mean 7.1 to 7.8 years. Matched cohort events: Death 213/7925 vs. 
321/7925 Adjusted HR 0.60 (0.45-0.67).  
Death according to cause:  
CAD 15/7925 vs. 33/7925 Adjusted HR 0.41 
(0.21-0.78).  
Stroke 7/7925 vs. 11/7925 Adjusted HR 0.43 
(0.14-1.30),  
CV death 55/7925 vs.. 104/7925, Adjusted HR 
0.51 (0.36–0.73) 
Adams 2012 Roux-en-Y gastric bypass 
surgery performed at the same 
surgical center. 
Non-intervened severely obese 
controls seeking surgery. 
Median follow up 5.8 years. Crude events death 12/418 vs. 17/738. 
Unadjusted RR 1.25 (0.60 – 2.58) 
Arterburn 
2013 
Bariatric surgery based on 
ICD-9 and CPT-4 procedure 
codes. 
Nonsurgical usual medical 
care. 
Up to 2 years. Death: 5/1395 vs. 484/62322, adjusted HR 0.54 
(0.22-1.23). 
Busetto 
2007 
Lap-Band Adjustable Gastric 
Banding System. 
Morbidly obese patients seen 
in outpatients seeking 
treatment for obesity. 
Mean 5.6 to 7.2 years. Death: 8/821 vs. 32/821, adjusted RR 0.36 
(0.16-0.79). 
Christou 
2004 
Open Roux en Y gastric 
bypass, vertical banded 
gastroplasty and laparoscopic 
RY gastric bypass. 
Controls with morbid obesity 
on ICD9 codes for treatment in 
hospital, treatment by a 
physician or as an indication 
for prescription, as well as 
never having surgery for the 
treatment for severe obesity. 
Mean 2.5-2.6 year but 
outcomes followed up to 5 
years. 
Death: n=7 (0.68%) vs. n=354 (6.17%), 
unadjusted relative risk reduction 0.11 (0.04-
0.27). 
Flum 2004 Gastric bypass. Hospital diagnosis of morbid 
obesity. 
Follow up 15 years. Death adjusted HR 0.67 (0.54-0.85). 
Gentileschi 
2012 
Laparoscopic gastric banding, 
laparoscopic sleeve 
Non-operated controls. 29.2 to 38.2 months. Crude events death 1/208 vs. 4/81. 
 gastrectomy and laparoscopic 
gastric banding. 
Johnson 
2013 
Bariatric surgical patients 
identified by primary ICD-9 
code. 
Control patients were 
moderately to severely obese 
patients with T2DM not 
undergoing a bariatric 
procedure. 
Median follow up median of 
19.0 to 21.2 months. 
Macrovascular event (MI, stroke, death) 
propensity matched adjusted HR 0.32 (0.19-
0.54). Crude events MI 8/2580 vs. 241/13371, 
stroke 11/2580 vs. 214/13371, death 41/2580 
vs. 985/13371. 
Maciejewski 
2011 
Batriatric procedures. Nonsurgical controls. Mean 6.7 years. Death adjusted HR 0.94 (0.64-1.39). 
Miranda 
2012 
First bariatric procedure, 95% 
Roux-en-Y gastric bypass. 
Non-operative management 
for obesity at Mayo Clinic. 
Follow up time of 5.9 to 8.5 
years. 
Death adjusted HR 0.76 (0.60-0.96). 
Peeters 
2007 
Laparoscopic adjustable 
gastric banding. 
Patients were a community 
control cohort. 
Median follow up 1 month to 
14.6 years.  Follow up 
censored at 5 and 10 years. 
Death adjusted HR 0.28 (0.10-0.85). 
Scott 2013 Bariatric surgery coded as 
ICD-9 codes 44.38, 44.39 and 
44.95. 
Surgical controls with 
orthopaedic procedures and 
gastrointestinal procedures. 
Mean of 13.7 to 25.8 months. Adjusted HR after pooling both control arms: 
MI: 0.54 (0.44-0.67) 
Stroke: 0.59 (0.37 – 0.95) 
Death: 0.60 (0.34 – 1.07) 
CV composite (MI, stroke, death): 0.59 (0.40 – 
0.88) 
Sjostrom 
2007 and 
2012 
Nonadjustable or adjustable 
banding, vertical banded 
gastroplasty and gastric 
bypass surgery. 
Obese patients had customary 
treatment for obesity. 
Mortality follow up mean 
10.9 years.CV events median 
follow up 14.7 years. 
Adjusted HR 
Death 0.71 (0.54-0.92). 
Cardiovascular events (fatal or non-fatal MI 
and stroke) 0.67 (0.54-0.83),  
MI 0.71 (0.54-0.94),  
Stroke adjusted HR 0.66 (0.49-0.90).  
Sowemimo 
2007 
Roux-en-Y gastric bypass, 
except 7 cases of adjustable 
gastric banding. 
Non-operated controls. Unclear. Death adjusted HR 0.18 (0.09-0.35). 
MI=myocardial infarction, ICD=International Classification of Disease, HR=hazard ratio, RR=relative risk 
 
 Supplementary Table 1: Results of studies 
 
Study Surgical 
group 
Control 
group 
Deaths in surgical vs. 
control. 
CV composite in 
surgical vs. control. 
MI in surgical vs. 
control. 
Stroke in surgical vs. 
control. 
Adams 2007 7,925 7925 213/7925 vs. 321/7925, 
adjusted HR 0.60 (0.45-
0.67) 
55/7925 vs. 104/7925 
Adjusted HR 0.51 (0.36 
– 0.73) 
 
15/7925 vs. 33/7925, 
adjusted HR 0.41 (0.21-
0.78) 
7/7925 vs. 11/7925, 
adjusted HR 0.51 (0.36-
0.73) 
Adams 2012 418  417 
control 1 
and 321 
control 2 
12/418 vs. 17/738, 
unadjusted RR 1.25 
(0.60-2.58) 
   
Arterburn 2013 1395 62,322 5/1395 vs. 484/62322, 
adjusted HR 0.54 (0.22-
1.23) 
   
Busetto 2007 821 821 8/821 vs. 32/821, adjusted 
RR 0.36 (0.16-0.79) 
   
Christou 2004 1,035 5,746 7/1035 vs. 354/5746, 
unadjusted RR reduction 
0.11 (0.04-0.27) 
   
Flum 2004 3,328 62,781 11.8% (393/3328) vs. 
16.3% (10233/62781), 
adjusted HR 0.67 (0.54-
0.85) 
   
Gentileschi 
2012 
208 81 1/208 vs. 4/81    
Johnson 2013 2,580 13,371 41/2580 vs. 985/13371 
Crude OR 0.20 (0.15 – 
0.27) 
19/2580 vs. 455/13371 
Adjusted HR 0.32 (0.19-
0.54) 
8/2580 vs. 241/13371 
Crude OR 0.17 (0.08-0.35) 
11/2580 vs. 214/13371 
Crude OR 0.26 (0.14-
0.48) 
Maciejewski 
2011 
847 847 6.7% (57/847) vs. 12.8% 
(108/847), adjusted HR 
0.94 (0.64-1.39) 
   
Miranda 2012 2,020 2,907 109/2020 vs. 304/2907, 
adjusted HR 0.76 (0.60-
0.96) 
   
 Peeters 2007 966 2,119 4/966 vs. 225/2119, 
adjusted HR 0.28 (0.10-
0.85) 
   
Scott 2013 4,747 3066 
control 1 
and 1327 
control 2 
82/4747 vs. 215/3066 vs. 
143/1327, adjusted HR 
0.54 (0.44-0.67) 
99/4747 vs. 234/3066 vs. 
116/1327, adjusted HR 
0.59 (0.40-0.88) 
81/4747 vs. 186/3066 vs. 
95/1327, adjusted HR 0.54 
(0.44-0.67) 
18/4747 vs. 48/3066 vs. 
21/1327, adjusted HR 
0.59 (0.37-0.95) 
Sjostrom 2007 
and 2012 
2,010 2,037 101/2010 vs. 129/2037, 
adjusted HR 0.71 (0.54-
0.92) 
234/2010 vs. 199/2037, 
adjusted HR 0.67 (0.54-
0.83) 
122/2010 vs. 136/2037, 
adjusted HR 0.71 (0.54-
0.94) 
93/2010 vs. 111/2037 
Sowemimo 
2007 
908 112 2.9% (26/908) vs. 14.3% 
(16/112), adjusted HR 
0.18 (0.09-0.35) 
   
 
 
 
 Figure 1: Flow diagram of study selection 
 
 Figure 2: Meta-analyses of mortality risk after bariatric surgery as compared to no 
surgery  
 
 Figure 3: Meta-analysis of risk of myocardial infarction after bariatric surgery 
compared to no surgery 
 
 Figure 4: Meta-analysis of stroke risk after bariatric surgery as compared to no 
surgery 
 
 Figure 5: Meta-analyses of adverse cardiovascular events risk after bariatric surgery 
as compared to no surgery 
 
 Supplement Data 1: Search Strategy 
 
EMBASE, MEDLINE; ((bariatric surgery) AND ((acute coronary syndrome) OR 
(ischemic heart disease) OR (ischaemic heart disease) OR (coronary heart disease) 
OR (stroke) OR (cerebrovascular accident) OR (mortality) OR (cardiovascular 
disease))).ti,ab. 
